Brief introduction of the Carelife Non-invasive Blood Glucose Monitor:
1. Product background
Data from the IDF Diabetes Atlas 10th edition reports a continued global increase in diabetes prevalence, confirming diabetes as a significant global challenge to the health and well-being of individuals, families and societies. 537 million adults (20-79 years) are living with diabetes - 1 in 10. This number is predicted to rise to 643 million by 2030 and 784 million by 2045. 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes.
There are about 100 million people with diabetes in China and more than 100 million people with Pre-diabetics.
These people need to check their blood glucose changes at any time.
2. Traditional blood glucose meters
Portable, minimally invasive, painful, easy to be infected, needs consumable materials
3. Carelife Non-Invasive Blood Glucose Monitor
√ Portable, non-invasive, no need for blood collection, no pain
√ Glucose level can be measured in only 60 seconds, continuously detecting
√ High correlation coefficient (more than 87%) compared with medically approved venous biochemical standards
√ Many health parameters, high sensor integration, makes counterfeiting almost impossible
√ No consumables, the overall product cost is lower than the traditional minimally invasive glucose meter and other non-invasive blood glucose monitors
√ Personalized medical care, health management, cloud computing and other business models with broad application prospects